SCHEMBL4715714

SCHEMBL4715714

O=C(c1cccc(N2Cc3cccc(Cl)c3C2=O)c1)N1CCN(CCc2ccccc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 1/20 0.57
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
KCNH2 Q12809 1/20 0.55
LMNA P02545 2/20 0.50
SIGMAR1 Q99720 2/20 0.49
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
HTR2A P28223 4/20 0.45
HTR2C P28335 2/20 0.45
HTR2B P41595 2/20 0.45
THRB P10828 1/20 0.44
ADRB2 P07550 1/20 0.43
DRD2 P14416 2/20 0.43
PARP1 P09874 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4714259 0.92 BDKRB1 (0.60) BDKRB1MEN1KMT2ALMNATSHR
SCHEMBL4712656 0.87 BDKRB1 (0.59) BDKRB1MEN1KMT2ASIGMAR1L3MBTL1
SCHEMBL4714797 0.86 BDKRB1 (0.58) BDKRB1MEN1KMT2ALMNATSHR
SCHEMBL4713885 0.85 BDKRB1 (0.57) BDKRB1MEN1KMT2ALMNATSHR
SCHEMBL4717372 0.82 BDKRB1 (0.56) BDKRB1KCNH2SMN1; SMN2HTR2AHTR2C
SCHEMBL4717437 0.81 BDKRB1 (0.60) BDKRB1MEN1KMT2ALMNAHTR2A
SCHEMBL4716862 0.81 BDKRB1 (0.64) BDKRB1MEN1KMT2ALMNATSHR
SCHEMBL4760693 0.81 BDKRB1 (0.66) BDKRB1LMNATSHRMAPK1SMN1; SMN2
SCHEMBL4713388 0.81 BDKRB1 (0.56) BDKRB1MAPK1L3MBTL1HTR2AHTR2C
SCHEMBL4716396 0.80 BDKRB1 (0.61) BDKRB1MEN1KMT2AKCNH2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US claimed
EP-1877401-A2 NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM Elan Pharmaceuticals Inc. (US) 2008-01-16 EP disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
WO-2006113140-A2 NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM ELAN PHARMACEUTICALS, INC. (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism BDKRB1, BDKRB2, NPBWR1 BDKRB1 1/4885MEN1 997/4885KMT2A 4091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.